Skip to main content

Want a detailed portfolio tracker?

SERA
NASDAQ
$2.10

Sera Prognostics Inc Class A (SERA)

Sera Prognostics Inc. is a pioneering force in maternal-fetal health, focusing on cutting-edge diagnostic solutions designed to enhance pregnancy outcomes. Its flagship product, the PreTRM test, harnesses a unique biomarker platform to accurately evaluate the risk of preterm birth, enabling healthcare providers to implement timely and impactful interventions. With a steadfast commitment to advancing prenatal diagnostics and addressing pivotal health challenges, Sera is strategically positioned for significant growth within the maternal health sector, offering investors compelling opportunities for long-term value creation.
Website: https://www.sera.com
68 analysts
Buy
Target: $5.50 (+161.90%)

Market Cap

$109M

Free Cash Flow Yield

-25.40%

Beta (5Y)

1.08

Price Chart

Valuation
Market Cap$109M
P/S1483.91
P/B1.26
Profitability
Total Revenue (TTM)$57K
Gross Profit (TTM)-$109K
EBITDA-$31M
Operating Margin-66857%
EPS-$0.65
Financial Health
Debt-to-Equity3.7%
Free Cash Flow Yield-25.40%
Growth & Risk
EPS 5Y CAGR-9.16%
Revenue 5Y CAGR+13.70%
FCF 5Y CAGR+7.30%
Beta (5Y)1.08
Sharpe Ratio-0.13